OUR EXPERT NETWORK

• Beyond Better Models: Why The Future Of AI-Designed mRNA Depends On More Relevant Biological Data

  AI can optimize mRNA only if it's trained on biologically relevant data. Better therapeutic datasets — not just better algorithms — will drive the next generation of RNA medicines.

• The Delivery Challenge For In Vivo Cell Engineering

  As RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.

• Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1)

  SynaptixBio CEO Dan Williams explains how the company selected an ASO for TUBB4A leukodystrophy by balancing potency, safety, and translational rigor to advance a rare disease therapy.

• Nucleic Acid Ligases: Connecting The Pieces For Sustainable And Scalable Production Of Oligonucleotide Therapeutics

  Chemoenzymatic ligation could overcome the scalability and sustainability limits of traditional oligonucleotide manufacturing, enabling more efficient RNA drug production.

• Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics

  CircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.